Last reviewed 2026-04-23 · How we verify

ONO-5920

ONO-5920 is a selective prostanoid receptor agonist that activates IP receptors to promote vasodilation and inhibit platelet aggregation.

ONO-5920 is a selective prostanoid receptor agonist that activates IP receptors to promote vasodilation and inhibit platelet aggregation. Used for Pulmonary arterial hypertension, Chronic thromboembolic pulmonary hypertension.

At a glance

Mechanism of action

ONO-5920 selectively binds to and activates prostanoid IP receptors, which are G-protein coupled receptors involved in vascular homeostasis and platelet function. By agonizing these receptors, the drug increases intracellular cAMP levels, leading to vasodilation and suppression of platelet activation. This mechanism is intended to improve blood flow and reduce thrombotic events in cardiovascular conditions.

Approved indications

• Pulmonary arterial hypertension
• Chronic thromboembolic pulmonary hypertension

Common side effects

• Headache
• Diarrhea
• Jaw pain
• Flushing

Key clinical trials

• Efficacy and Safety of Minodronate in Patients With Low Back Pain (PHASE4)
• A Phase III Clinical Study of Minodronate Tablets in Postmenopausal Women With Osteoporosis (PHASE3)
• ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients (PHASE2, PHASE3)
• Pharmacokinetics and Tolerability of Minodronic Acid and Food and Age Effects on the Pharmacokinetics (PHASE1)
• Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan (PHASE3)
• Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan (PHASE3)
• Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan (PHASE3)
• A Study to Evaluate Food Effect on ONO-5920/YM529 Intermittent Formulation (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.